en · de · es
cardarine-notes.peptides1004.com › Data › Preclinical Findings And Safety Signals — Research Overview

Preclinical Findings And Safety Signals — Research Overview

By Editorial Desk · published 2026-02-26 · last reviewed 2026-04-17 · Data

LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Regulation and Detection

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Cardarine Identity and Mechanism

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.

Related pages on this site

Mechanism and Detection

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Notes from published material

== Pre-trial proceedings == The first evidence that the prosecution introduced against Agüero, was immediately after her arrest, alleging that Agüero was behind every case, both deaths and decompensations, and that Agüero herself was in the place of the incidents, further alleging that she was the one who notified the doctors and other medical personnel that an emergency with a newborn was underway. On the same day that the prosecution introduced their first accusation, the court in charge of the pre-trial procedures, ordered psychiatric and psychological evaluations of Agüero, to later dictate pre-trial detention. In January 2023, the psychiatric evaluators determined that Agüero knows right from wrong and that she does not suffer from any mental disorder. The psychiatrists further argued that Agüero tried to "manipulate the interview" and that she has difficulties in regards to feeling what others do. After the evaluation, Agüero's indictment was confirmed. The prosecution alleged that in November 2021, Agüero searched on Google "how to dose potassium and insulin injections in newborns." Agüero denied that she searched "how to apply potassium injections" on Google and alleged that she does not have the knowledge to perform such a procedure. Another accusation argued that Agüero concealed the syringes with which she allegedly injected the babies with potassium, under her sleeves, with other medical personnel noting that she went to work with long-sleeved shirts even on hot summer days.

=== CD8+ T-cells === Tetramer stains usually analyze cytotoxic T lymphocyte (CTL) populations. CTLs are also called CD8+ T-cells, because they have CD8 co-receptors that bind to MHC class I molecules. Most cells in the body express MHC class I molecules, which are responsible for processing intracellular antigens and presenting at the cell's surface. If the peptides being presented by MHC class I molecules are foreign—for example, derived from viral proteins instead of the cell's own proteins—the CTL with a receptor that matches the peptide will destroy the cell. Tetramer stains allow for the visualization, quantification, and sorting of these cells by flow cytometry, which is extremely useful in immunology. T-cell populations can be tracked over the duration of a virus or after the application of a vaccine. Tetramer stains can also be paired with functional assays like ELIspot, which detects the number of cytokine secreting cells in a sample.

The fluid is transudative in nature which facilitates continuous exchange of oxygen, carbon dioxide and metabolites between blood and synovial fluid. This is especially important since it is the major source of metabolic support for articular cartilage. Under normal conditions synovial fluid contain <100/mL of leucocytes in which majority are monocytes.

== Diagnostic criteria == According to the WHO criteria as revised in 2000, a cardiac troponin rise accompanied by either typical symptoms, pathological Q waves, ST elevation or depression or coronary intervention are diagnostic of MI. Previous WHO criteria formulated in 1979 put less emphasis on cardiac biomarkers; according to these, a patient is diagnosed with myocardial infarction if two (probable) or three (definite) of the following criteria are satisfied:

Sources: en.wikipedia.org

Background from the literature

In immunology, the mononuclear phagocyte system or mononuclear phagocytic system (MPS), also known as the macrophage system, is a part of the immune system that consists of the phagocytic cells located in reticular connective tissue. The cells are primarily monocytes and macrophages, and they accumulate in lymph nodes and the spleen. The Kupffer cells of the liver and tissue histiocytes are also part of the MPS. The mononuclear phagocyte system and the monocyte macrophage system refer to two different entities, often mistakenly understood as one. "Reticuloendothelial system" is an older term for the mononuclear phagocyte system, but it is used less commonly now, as it is understood that most endothelial cells are not macrophages. The mononuclear phagocyte system is also a somewhat dated concept trying to combine a broad range of cells, and should be used with caution.

Muscular dystrophy is a group of disorders associated with progressive muscle weakness and loss of muscle mass. These disorders are caused by genetic mutations. The disease affects between 19.8 and 25.1 per 100,000 person-years globally. There are more than 30 types of muscular dystrophy. Depending on the type, muscular dystrophy can affect a person's heart and lungs, and can affect the ability to move, walk, and perform daily activities. The most common types include:

The RF's intention was partly to test whether or not the British would attempt to block this bill after Gibbs had granted Royal Assent to it, but this issue never came to a head because Sandys persuaded Field not to forward it to Gibbs for ratification on the grounds that it had not been unanimously passed. Lord Salisbury, one of Southern Rhodesia's main supporters in Britain, despaired at Field's lack of action, telling Welensky that as he saw it "the simple time to have declared independence, whether right or wrong, would have been when the Federation came to an end". The RF hierarchy interpreted this latest backtrack by Field as evidence that he would not seriously challenge the British on the independence issue, and forced his resignation on 13 April 1964. Smith accepted the Cabinet's nomination to take his place.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

Is cardarine legal?

Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.

Network